Ahmed H, Petkar M, Steinhoff M (2023) Successful treatment of rare linear lichen planopilaris with Ixekizumab. J Dermatolog Treat 34(1):2201364

PubMed  Google Scholar 

Alaizari NA, Al-Maweri SA, Al-Shamiri HM, Tarakji B, Shugaa-Addin B (2016) Hepatitis C virus infections in oral lichen planus: a systematic review and meta-analysis. Aust Dent J 61(3):282–287

CAS  PubMed  Google Scholar 

Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, Massarotti EM, Bush ML (2009) Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 61(1):104–111

PubMed  Google Scholar 

Belcadi J, Ali SO, El Ouartih I, Znati K, Senouci K, Meziane M (2024) Secukinumab-induced lichen planus. Jeadv Clinical Practice 3(2):729–730

Google Scholar 

Bieber T (2020) Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy 75(1):54–62

CAS  PubMed  Google Scholar 

Blegvad C, Skov L, Zachariae C (2019) Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Rev Clin Immunol 15:111–121

CAS  PubMed  Google Scholar 

Boch K, Langan EA, Kridin K, Zillikens D, Ludwig RJ, Bieber K (2021) Lichen Planus. Front Med (Lausanne) 8:737813

PubMed  Google Scholar 

Boyd AS, Neldner KH (1991) Lichen planus. J Am Acad Dermatol 25:593–619

CAS  PubMed  Google Scholar 

Capusan TM, Herrero-Moyano M, Martinez-Mera CR, Freih-Fraih AW, Dauden E (2018) Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event? JAAD Case Rep 4(6):521–523

PubMed  PubMed Central  Google Scholar 

Cassol-Spanemberg J, Rodriguez-de Rivera-Campillo ME, Otero-Rey EM, Estrugo-Devesa A, Jane-Salas E, Lopez-Lopez J (2018) Oral lichen planus and its relationship with systemic diseases. A review of evidence. J Clin Exp Dent 10(9):e938–e944

PubMed  PubMed Central  Google Scholar 

Chemli S, Rym D, Jebali A, Hammami W (2006) Association lichen planus and ulcerative colitis. A case report. Tunis Med 84(1):65–67

PubMed  Google Scholar 

Ch’en PY, Song EJ (2023) Lichen planus pemphigoides successfully treated with dupilumab. JAAD Case Rep 31:56–58

PubMed  Google Scholar 

Cigic L, Gavic L, Simunic M, Ardalic Z, Biocina-Lukenda D (2015) Increased prevalence of celiac disease in patients with oral lichen planus. Clin Oral Investig 19(3):627–635

PubMed  Google Scholar 

Cohen PR, Kurzrock R (2014) Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J 20(1):21241

PubMed  Google Scholar 

Croxtall JD (2011) Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 71(13):1733–1753

CAS  PubMed  Google Scholar 

Daye M, Temiz SA, Gümüş S, Kılınç F (2021) Secukinumab-induced oral lichen planus: a report of case and review of literature. Istanbul Med J 22(3):235–237

Google Scholar 

Deeks ED (2019) Dupilumab: A review in moderate to severe asthma. Drugs 79(17):1885–1895

CAS  PubMed  Google Scholar 

Desai S, Nussbaum D, Friedman A (2023) 44511 Double trouble: graham-little-piccardi-lasseur syndrome and hidradenitis suppurativa, is there a link? J Am Acad of Dermatol 89(3):AB39

Google Scholar 

Didona D, Caposiena Caro RD, Sequeira Santos AM, Solimani F, Hertl M (2022) Therapeutic strategies for oral lichen planus: State of the art and new insights. Front Med (Lausanne) 9:997190

PubMed  Google Scholar 

Didona D, Pollmann R, Solimani F, Eming R, Hertl M (2021) 47th annual meeting of the arbeitsgemeinschaft dermatologische forschung (ADF): virtual, March 04-06, 2021. Exp Dermatol 30(3): e1–e135

Dinarello CA (2018) Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 281(1):8–27

CAS  PubMed  PubMed Central  Google Scholar 

Doolan B, Anderton H, Christie M, Dolianitis C (2018) Cutaneous lichen planus induced by secukinumab. Australas J Dermatol 59:60–61

Google Scholar 

Eakes J, Hatch L, Hennessy K, Ravichandran S, Ayoubi N, Fourzali K, Yi J, Krenitsky A, Kucharik A, Correa L (2024) 50699 Pembrolizumab-Induced lichenoid drug eruption successfully treated with dupilumab – a case report. J Am Acad Dermatol 91:AB70

Google Scholar 

El-Howati A, Thornhill MH, Colley HE, Murdoch C (2023) Immune mechanisms in oral lichen planus. Oral Dis 29(4):1400–1415

PubMed  Google Scholar 

Ellgehausen P, Elsner P, Burg G (1998) Drug-induced lichen planus. Clin Dermatol 16(3):325–332

CAS  PubMed  Google Scholar 

Fargnoli MA-O, Bardazzi F, Bianchi L, Dapavo P, Fabbrocini G, Gisondi PA-O, Micali G, Offidani AM, Pellacani G, Skroza NA-O, Angileri RG, Burlando MA-O, Campanati AA-O, Carrera CG, Chiricozzi AA-O, Conti A, Simone CA-O, Di Lernia V, Errichetti E, Galluzzo MA-O, Guarneri CA-O, Lasagni C, Lembo S, Loconsole F, Megna MA-O, Musumeci ML, Prignano FA-O, Richetta AG, Trovato EA-O, Venturini M, Peris K, Pinton PC (2023) Brodalumab for the treatment of moderate-to-severe psoriasis: an expert delphi consensus statement. J Clin Med. https://doi.org/10.3390/jcm12103545

PubMed  PubMed Central  Google Scholar 

Lowe NJ, Cudworth AG, Clough SA, Bullen MF (1976) Carbohydrate metabolism in lichen planus. Br J Dermatol 95(1):9-12

Fiocco Z, Kupf S, Patzak L, Kammerer T, Pumnea T, French LE, Reinholz M (2021) Quality of life and psychopathology in lichen planus: a neglected disease burden. Acta Derm Venereol 101(12):adv00619

PubMed  Google Scholar 

Fletcher JM, Moran B, Petrasca A, Smith CM (2020) IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol 201(2):121–134

CAS  PubMed  PubMed Central  Google Scholar 

Frampton JE, Blair HA (2018) Dupilumab: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol 19(4):617–624

PubMed  Google Scholar 

Fujita Y, Sugai T, Maya Y, Inamura E, Hirano Y, Shimizu S (2023) Secukinumab-induced oral lichen planus in a psoriatic arthritis patient ameliorated after a switch to risankizumab. J Dermatol 50(6):824–827

CAS  PubMed  Google Scholar 

Gajraj FA, Zahir J, Adereti C, Gajraj MH (2023) A case report and literature review of the role of dupilumab in the management of lichen planus: cause or treatment? Cureus 15(7):e41274

PubMed  PubMed Central  Google Scholar 

Gara SK, Guntipalli P, Marzban S, Taqi M, Aryal V, Khan QUA, Shah SA, Akbariromani H, Salinger D, Diaz-Miret M (2023) Clinical outcomes of ustekinumab in inflammatory bowel disease. Cureus 15(10):e46833

PubMed  PubMed Central  Google Scholar 

Ghiam N, Ojong O, Vasile G, Romanelli P, Kerdel F (2020) Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis. Dermatol Online J 26(12):13030

Google Scholar 

Ghoreschi K, Balato A, Enerback C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397(10275):754–766

CAS  PubMed  Google Scholar 

Gorouhi F, Davari P, Fazel N (2014) Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. Sci World J 2014:742826

Google Scholar 

Guo L, Zhang H, Chen B (2017) Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 8:410

CAS  PubMed  PubMed Central  Google Scholar 

Halevy S, Shai A (1993) Lichenoid drug eruptions. J Am Acad Dermatol 29(2 Pt 1):249–255

CAS  PubMed  Google Scholar 

Heidari N, Heidari A, Eghbali S, Pishraft-sabet H, Hajikarim-Hamedani A, Ghane Y, Lotfi Z, Goodarzi A (2025) The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials. Autoimmun Rev 24(7):103818

CAS  PubMed  Google Scholar 

Husein-ElAhmed H, Steinhoff M (2022) Potential role of INTERLEUKIN-17 in the pathogenesis of oral lichen planus: a systematic review with META-analysis. J Eur Acad Dermatol Venereol 36(10):1735–1744

CAS  PubMed  Google Scholar 

Ioannides D, Vakirlis E, Kemeny L, Marinovic B, Massone C, Murphy R, Nast A, Ronnevig J, Ruzicka T, Cooper SM, Trueb RM, Pujol Vallverdu RM, Wolf R, Neumann M (2020) European S1 guidelines on the management of lichen planus: a cooperation of the European dermatology forum with the european academy of dermatology and venereology. J Eur Acad Dermatol Venereol 34(7):1403–1414

CAS  PubMed  Google Scholar 

Ismail FF, Sinclair R (2020) Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin-23/interleukin-17 pathway in the pathogenesis of lichen planus. Australas J Dermatol 61(2):e244–e245

PubMed  Google Scholar 

Kassels A, Elsensohn AN, Kraus CN (2024) Lichen planus is associated with other autoimmune conditions: A retrospective population-level study. J Am Acad Dermatol 90(3):650–652

PubMed  Google Scholar 

Kazemi S, Murphrey M, Hawkes JE (2022) Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab. JAAD Case Rep 30:108–110

PubMed  PubMed Central